Evidence map›Paper›PMID 29506489›Full record

ArticleBMC cancer2018

AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.

Sanja Brolih, Scott K Parks, Valérie Vial, Jérôme Durivault, Livio Mostosi, Jacques Pouysségur, Gilles Pagès, Vincent Picco

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Targeting Akt in cancer for precision therapy.Journal of hematology & oncology · 2021
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sanja BrolihCentre Scientifique de Monaco, Department of Medical Biology, 8 Quai Antoine Ier, Monaco, Principality of Monaco.
Scott K ParksCentre Scientifique de Monaco, Department of Medical Biology, 8 Quai Antoine Ier, Monaco, Principality of Monaco.
Valérie VialCentre Scientifique de Monaco, Department of Medical Biology, 8 Quai Antoine Ier, Monaco, Principality of Monaco.
Jérôme DurivaultCentre Scientifique de Monaco, Department of Medical Biology, 8 Quai Antoine Ier, Monaco, Principality of Monaco.
Livio MostosiCentre Scientifique de Monaco, Department of Medical Biology, 8 Quai Antoine Ier, Monaco, Principality of Monaco.
Jacques PouysségurCentre Scientifique de Monaco, Department of Medical Biology, 8 Quai Antoine Ier, Monaco, Principality of Monaco.
Gilles PagèsCentre Scientifique de Monaco, Department of Medical Biology, 8 Quai Antoine Ier, Monaco, Principality of Monaco.
Vincent PiccoCentre Scientifique de Monaco, Department of Medical Biology, 8 Quai Antoine Ier, Monaco, Principality of Monaco. vpicco@centrescientifique.mc.ORCID 0000-0001-5251-1521
Scientific Centre of Monaco · MCCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn mammals, the AKT/PKB protein kinase family comprises three members (AKT1-3). PI3-Kinase (PI3K), a key oncogene involved in a wide variety of cancers, drives AKT activity. Constitutive activation of the PI3K/AKT pathway has been associated with tumorigenic properties including uncontrolled cell proliferation and survival, angiogenesis, promotion of cellular motility, invasiveness and metastasis. However, AKT1 activity has also been recently shown to repress the invasive properties of breast cancer cells in specific contexts.

methodsThis study used both pharmacological and shRNA approaches to inhibit AKT function, microscopy to characterize the cellular morphology, 3D spheroid models to assess migratory and invasive cellular capacities and a phenotypic screening approach based on electrical properties of the cells.

resultsHere we demonstrate that the alternative action of AKT1 on invasive properties of breast cancers can be extended to head and neck carcinomas, which exhibit constitutive activation of the PI3K/AKT pathway. Indeed, inhibition of AKT1 function by shRNA or a specific pharmacological inhibitor resulted in cellular spreading and an invasive phenotype. A phenotypic screening approach based on cellular electrical properties corroborated microscopic observations and provides a foundation for future high-throughput screening studies. This technique further showed that the inhibition of AKT1 signaling is phenocopied by blocking the mTORC1 pathway with rapamycin.

conclusionOur study suggests that the repressive action of PI3K/AKT1 on cellular invasive properties may be a mechanism common to several cancers. Current and future studies involving AKT inhibitors must therefore consider this property to prevent metastases and consequently to improve survival.

Indexed as

Cell MovementCell ProliferationApoptosisHead and Neck NeoplasmsHeterocyclic Compounds, 3-RingHumansNeoplasm InvasivenessPhosphatidylinositol 3-KinasesPhosphorylationProto-Oncogene Proteins c-aktRNA, Small InterferingSignal TransductionTumor Cells, CulturedAKT1 protein, humanHeterocyclic Compounds, 3-RingMK 2206Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Small InterferingAdhesionAKT/PKBCancerEpithelial-mesenchymal transitionHead and neck squamous cell carcinomaInvasionMetastasisMigrationPhenotypic screening

Identifiers

PMID29506489
PMCPMC5836445
OpenAlexW2796522343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.